• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Appearance of Pancreatic Sufficiency and Discontinuation of Pancreatic Enzyme Replacement Therapy in Children with Cystic Fibrosis on Ivacaftor.

作者信息

Hutchinson Ingrid, McNally Paul

机构信息

Children's Health Ireland at Crumlin Dublin, Ireland and.

Royal College of Surgeons in Ireland Dublin, Ireland.

出版信息

Ann Am Thorac Soc. 2021 Jan;18(1):182-183. doi: 10.1513/AnnalsATS.202006-614RL.

DOI:10.1513/AnnalsATS.202006-614RL
PMID:32931706
Abstract
摘要

相似文献

1
Appearance of Pancreatic Sufficiency and Discontinuation of Pancreatic Enzyme Replacement Therapy in Children with Cystic Fibrosis on Ivacaftor.接受依伐卡托治疗的囊性纤维化患儿胰腺功能充足的表现及胰酶替代疗法的停用
Ann Am Thorac Soc. 2021 Jan;18(1):182-183. doi: 10.1513/AnnalsATS.202006-614RL.
2
Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor.依伐卡托治疗后囊性纤维化患者胰腺功能持续恢复。
Pediatr Pulmonol. 2020 Dec;55(12):3381-3383. doi: 10.1002/ppul.25065. Epub 2020 Oct 22.
3
Effects of Ivacaftor in Three Pediatric Siblings With Cystic Fibrosis Carrying the Mutations G551D And F508del.依伐卡托对三名携带G551D和F508del突变的囊性纤维化儿科同胞的影响。
Arch Bronconeumol (Engl Ed). 2018 Apr;54(4):232-234. doi: 10.1016/j.arbres.2017.09.012. Epub 2017 Nov 3.
4
Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations.能量平衡与依伐卡托治疗囊性纤维化门控突变导致体重增加的机制。
J Pediatr. 2018 Oct;201:229-237.e4. doi: 10.1016/j.jpeds.2018.05.018. Epub 2018 Jul 18.
5
Pancreatic enzyme prescription following ivacaftor licensing: A retrospective analysis of the US and UK cystic fibrosis registries.依伐卡托特获批后胰腺酶处方：美国和英国囊性纤维化注册研究的回顾性分析。
J Cyst Fibros. 2024 Jul;23(4):746-753. doi: 10.1016/j.jcf.2024.01.011. Epub 2024 Feb 10.
6
Time for a gut check: Pancreatic sufficiency resulting from CFTR modulator use.是时候检查一下肠道了：CFTR 调节剂使用导致的胰腺充分性。
Pediatr Pulmonol. 2019 Aug;54(8):E16-E18. doi: 10.1002/ppul.24353. Epub 2019 May 7.
7
Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.针对携带F508del-CFTR突变纯合子的6至11岁囊性纤维化儿童，鲁马卡托-依伐卡托治疗的长期安全性和有效性：一项3期开放标签扩展研究。
Lancet Respir Med. 2021 Jul;9(7):721-732. doi: 10.1016/S2213-2600(20)30517-8. Epub 2021 Jan 28.
8
[Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation].依伐卡托对囊性纤维化G551D突变儿童的真实世界有效性
An Pediatr (Engl Ed). 2019 Mar;90(3):148-156. doi: 10.1016/j.anpedi.2018.05.022. Epub 2018 Aug 6.
9
Ivacaftor in a G551D homozygote with cystic fibrosis.依伐卡托用于治疗一名患有囊性纤维化的G551D纯合子患者。
N Engl J Med. 2013 Sep 26;369(13):1280-2. doi: 10.1056/NEJMc1213681.
10
Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor.肠道电流测量可检测出接受依伐卡托治疗的携带G551D突变的囊性纤维化患者中突变型CFTR的激活情况。
Am J Respir Crit Care Med. 2015 Nov 15;192(10):1252-5. doi: 10.1164/rccm.201507-1271LE.

引用本文的文献

1
Pancreatic, nutritional and clinical outcomes in children 0-5 years with cystic fibrosis during the first 2 years of CFTR modulator therapy (PaNC): a multicentre prospective observational study protocol.囊性纤维化跨膜传导调节因子调节剂治疗（PaNC）前两年0至5岁囊性纤维化儿童的胰腺、营养和临床结局：一项多中心前瞻性观察研究方案
BMJ Open. 2025 Jul 30;15(7):e097071. doi: 10.1136/bmjopen-2024-097071.
2
Pancreatic enzyme prescription following ivacaftor licensing: A retrospective analysis of the US and UK cystic fibrosis registries.依伐卡托特获批后胰腺酶处方：美国和英国囊性纤维化注册研究的回顾性分析。
J Cyst Fibros. 2024 Jul;23(4):746-753. doi: 10.1016/j.jcf.2024.01.011. Epub 2024 Feb 10.
3
Going the Extra Mile: Why Clinical Research in Cystic Fibrosis Must Include Children.
更进一步：为何囊性纤维化的临床研究必须纳入儿童。
Children (Basel). 2022 Jul 20;9(7):1080. doi: 10.3390/children9071080.
4
Current clinical opinion on CFTR dysfunction and patient risk of pancreatitis: diagnostic and therapeutic considerations.当前关于 CFTR 功能障碍和胰腺炎患者风险的临床意见：诊断和治疗注意事项。
Expert Rev Gastroenterol Hepatol. 2022 Jun;16(6):499-509. doi: 10.1080/17474124.2022.2084072. Epub 2022 Jun 2.
5
Update in Pediatrics 2020.《2020年儿科学进展》
Am J Respir Crit Care Med. 2021 Aug 1;204(3):274-284. doi: 10.1164/rccm.202103-0605UP.
6
Challenges in the use of highly effective modulator treatment for cystic fibrosis.高效调节剂治疗囊性纤维化的应用挑战。
J Cyst Fibros. 2021 May;20(3):381-387. doi: 10.1016/j.jcf.2021.01.007. Epub 2021 Jan 30.